GSK Acquires RAPT Therapeutics for $2.2B to Gain Global Rights to Ozureprubart, a Long-Acting Anti-IgE Antibody Originally Developed in China

Jan 20, 2026 16:33 CST Updated 16:33

GSK

Pharmaceutical R&D Manufacturer

RAPT

Anti-cancer Biopharmaceuticals Manufacturer

Jiyu

Innovative Drug Developer

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircleMonitoringDisplay: Just nowGSK Announces Acquisition of U.S.-Listed RAPT Therapeutics, Inc.; Key Asset is Ozureprubart, a Long-Acting Anti-Immunoglobulin E (IgE) Monoclonal Antibody Currently in Phase IIb Clinical Development

The total acquisition amount is approximately 2.2 billion US dollars.

This product was initially developed by Jiyu, a subsidiary of Jemincare.In December 2024, the global rights (excluding Greater China) for RAPT JYB1904 were acquired for a $35 million upfront payment, up to $672.5 million in milestone payments, and a certain percentage of sales royalties.

References:

PharmaCircle Data;

Moxie Pharma pharma.bcpmdata.com (formerly known as Yirong Cloud Data);

https://www.businesswire.com；Etc.